Great news for patients with Chronic Kidney Disease! As explained in the last Press Release published by ERA-EDTA, two large randomized controlled studies show that SGLT2 inhibitors slow diabetic and non-diabetic CKD progression. These groundbreaking results are a big step forward for the treatment of kidney disease!
|